CG250 177LU
drug drugOn this page
Also known as CG250Cg250 (177lu)
Summary
Cg250 177Lu (CHEMBL3707297) is a phase-3 clinical-stage unknown; indicated across 1 condition including renal cell carcinoma.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Unknown
- Indications: 1 condition
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL3707297 |
| Name | CG250 177LU |
| Type | Unknown |
| Max phase | 3 |
Also known as: CG250, Cg250 177lu, Cg250 (177lu), CG250 177LU
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.
| Disease (in trials) | Phase | MONDO | EFO |
|---|---|---|---|
| renal cell carcinoma | 1 | MONDO:0005086 | EFO:0000681 |
Clinical trials
Total trials: 0.
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.